Gautam Behl

Gautam Behl

Auto-generated profile, based on publicly available information

Gautam Behl

Ocular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre, Waterford Institute of Technology, X91 K0EK Waterford, Ireland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MDMadhuri Dandamudi
Madhuri Dandamudi
PMPeter McLoughlin
Peter McLoughlin
GBGautam Behl
Gautam Behl
SRSweta Rani
Sweta Rani
LCLee Coffey
Lee Coffey
LFLaurence Fitzhenry
Laurence Fitzhenry
The current treatment for the acquired retinal vasculopathies involves lifelong repeated intravitreal injections of either anti-vascular endothelial growth factor (VEGF) therapy or modulation of inflammation with steroids. Consequently, any treatment modification that decreases this treatment burden for patients and doctors alike would be a welcome intervention. To that end, this research aims to develop a topically applied nanoparticulate system encapsulating a corticosteroid for extended drug release. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) supports the controlled release of the encapsulated drug, while surface modification of these NPs with chitosan might prolong the mucoadhesion ability leading to improved bioavailability of the drug. Triamcinolone acetonide (TA)-loaded chitosan-coated PLGA NPs were fabricated using the oil-in-water emulsion technique. The optimized surface-modified NPs obtained using Box-Behnken response surface statistical design were reproducible with a particle diameter of 334 ± 67.95 to 386 ± 15.14 nm and PDI between 0.09 and 0.15. These NPs encapsulated 55–57% of TA and displayed a controlled release of the drug reaching a plateau in 27 h. Fourier-transform infrared spectroscopic (FTIR) analysis demonstrated characteristic peaks for chitosan (C-H, CONH2 and C-O at 2935, 1631 and 1087 cm−1, respectively) in chitosan-coated PLGA NPs. This result data, coupled with positive zeta potential values (ranged between +26 and +33 mV), suggests the successful coating of chitosan onto PLGA NPs. Upon coating of the NPs, the thermal stability of the drug, polymer, surfactant and PLGA NPs have been enhanced. The characteristics of the surface-modified NPs supports their use as potential candidates for topical ocular drug delivery for acquired retinal vasculopathies.

10 March 2016 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
GBGautam Behl
Gautam Behl
JIJaved Iqbal
Javed Iqbal
NONiall J. O’rEilly
Niall J. O’rEilly
PMPeter McLoughlin
Peter McLoughlin
LFLaurence Fitzhenry
Laurence Fitzhenry

12 July 2019 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PKParveen Kumar
Parveen Kumar
BLBo Liu
Bo Liu
GBGautam Behl
Gautam Behl

12 May 2016 in Nanomedicine
Verified
Journal Article
Closed access
KPKetan Patel
Ketan Patel
RDRavi Doddapaneni
Ravi Doddapaneni
NCNusrat Chowdhury
Nusrat Chowdhury
CBCedar Ha Boakye
Cedar Ha Boakye
GBGautam Behl
Gautam Behl
Mandip Singh SachdevaMandip Singh Sachdeva
Mandip Singh Sachdeva
Aim: Therapeutic efficacy of anticancer nanomedicine is compromised by tumor stromal barriers. The present study deals with the development of docetaxel loaded PEGylated liposomes (DTXPL) and to investigate the effect of tumor stroma disrupting agent, telmisartan, on anticancer efficacy of DTXPL. Methods: DTXPL was prepared using proprietary modified hydration method. Effect of oral telmisartan treatment on tumor uptake of coumarin-6 liposomes and anticancer efficacy of DTXPL was evaluated in orthotopic xenograft lung tumor bearing mice. Results: DTXPL (105.7 ± 3.8 nm) showed very high physical stability, negligible hemolysis, 428% enhancement in bioavailability with significantly higher intratumoral uptake. Marked reduction in collagen-I, MMP2/9 and lung tumor weight were observed in DTXPL+telmisartan group. Conclusion: Combination of DTXPL with telmisartan could significantly enhance clinical outcome in lung cancer.

18 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSANGEETA KUMARI
SANGEETA KUMARI
MDMadhuri Dandamudi
Madhuri Dandamudi
SRSweta Rani
Sweta Rani
EBElke Behaeghel
Elke Behaeghel
GBGautam Behl
Gautam Behl
LFLaurence Fitzhenry
Laurence Fitzhenry
Dry eye disease (DED) or keratoconjunctivitis sicca is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction. Symptoms include dryness, irritation, discomfort and visual disturbance, and standard treatment includes the use of lubricants and topical steroids. Secondary inflammation plays a prominent role in the development and propagation of this debilitating condition. To address this we have investigated the pilot scale development of an innovative drug delivery system using a dexamethasone-encapsulated cholesterol-Labrafac™ lipophile nanostructured lipid carrier (NLC)-based ophthalmic formulation, which could be developed as an eye drop to treat DED and any associated acute exacerbations. After rapid screening of a range of laboratory scale pre-formulations, the chosen formulation was prepared at pilot scale with a particle size of 19.51 ± 0.5 nm, an encapsulation efficiency of 99.6 ± 0.5%, a PDI of 0.08, and an extended stability of 6 months at 4 °C. This potential ophthalmic formulation was observed to have high tolerability and internalization capacity for human corneal epithelial cells, with similar behavior demonstrated on ex vivo porcine cornea studies, suggesting suitable distribution on the ocular surface. Further, ELISA was used to study the impact of the pilot scale formulation on a range of inflammatory biomarkers. The most successful dexamethasone-loaded NLC showed a 5-fold reduction of TNF-α production over dexamethasone solution alone, with comparable results for MMP-9 and IL-6. The ease of formulation, scalability, performance and biomarker assays suggest that this NLC formulation could be a viable option for the topical treatment of DED.

1 July 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
CBCedar H.A. Boakye
Cedar H.A. Boakye
KPKetan Patel
Ketan Patel
RDRavi Doddapaneni
Ravi Doddapaneni
ABArvind Bagde
Arvind Bagde
GBGautam Behl
Gautam Behl
Mandip Singh SachdevaMandip Singh Sachdeva
Mandip Singh Sachdeva